SALT
LAKE CITY, Jan. 6, 2025 /PRNewswire/ -- Sera
Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA),
focused on improving maternal and neonatal health by providing
innovative pregnancy biomarker information to doctors and patients,
today announced that the company will present at the 43rd Annual
J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco. Zhenya Lindgardt, President and
CEO, will present on January 16 at
9:45 a.m. PT and provide a company
update and discuss Sera's latest achievements.
A live webcast of the company's presentation as well as a
webcast replay will be available online from the Investors page of
the Company's website at www.seraprognostics.com.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company
dedicated to improving the lives of women and babies through
precision pregnancy care. Sera's mission is to provide early,
pivotal pregnancy information to improve the health of mothers and
newborns, resulting in reductions in the costs of healthcare
delivery. Sera has a robust pipeline of innovative diagnostic tests
focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera's precision medicine PreTRM® Test
reports to a physician the individualized risk of spontaneous
premature delivery in a pregnancy, enabling earlier proactive
interventions in women with higher risk. Sera Prognostics is
headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation
and is the leading cause of illness and death in newborns. The 2023
March of Dimes Report Card shows that, for the last five
consecutive years, more than one in ten infants is born prematurely
in the United States. Prematurity
is associated with a significantly increased risk of major
long-term medical complications, including learning disabilities,
cerebral palsy, chronic respiratory illness, intellectual
disability, seizures, and vision and hearing loss, and can generate
significant costs throughout the lives of affected children. The
annual health care costs to manage short- and long-term
complications of prematurity in the United States were
estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially
available blood-based biomarker test that provides an early,
accurate and individualized risk prediction for spontaneous preterm
birth in asymptomatic singleton pregnancies. The PreTRM® Test
measures and analyzes proteins in the blood that are highly
predictive of preterm birth. The PreTRM® Test permits physicians to
identify, during the weeks 18 through 20 of pregnancy, which women
are at increased risk for preterm birth and its complications,
enabling more informed, personalized clinical decisions based on
each woman's individual risk. The PreTRM® Test is ordered by a
medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy
Company, and PreTRM are trademarks or registered trademarks of Sera
Prognostics, Inc. in the United States and/or other
countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the date, time, content and
webcast replay availability of the Company's presentation at the
43rd Annual J.P. Morgan Healthcare Conference; and the company's
strategic directives under the caption "About Sera Prognostics,
Inc." These "forward-looking statements" are based on management's
current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied
by forward-looking statements. These risks and uncertainties
include, but are not limited to: net losses, cash generation, and
the potential need to raise more capital; revenues from the PreTRM
Test representing substantially all Company revenues to date; the
need for broad scientific and market acceptance of the PreTRM Test;
a concentrated number of material customers; our ability to
introduce new products; potential competition; our proprietary
biobank; critical suppliers; the COVID-19 pandemic and its
potential lingering impact on our operations, as well as the
business or operations of third parties with whom we conduct
business; estimates of total addressable market opportunity and
forecasts of market growth; potential third-party payer coverage
and reimbursement; new reimbursement methodologies applicable to
the PreTRM Test, including new CPT codes and payment rates for
those codes; changes in FDA regulation of laboratory-developed
tests; the intellectual property rights protecting our tests and
market position; and other factors discussed under the heading
"Risk Factors" contained in our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our periodic and current reports filed
with the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and the
Company undertakes no duty to update this information unless
required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302342451.html
SOURCE Sera Prognostics, Inc.
